markets

J. Edward Moreno3/10/25

Novo Nordisk dips after latest trial on its new weight-loss drug disappoints

Novo Nordisk shares fell after the results for the latest trial of its next-generation weight-loss shot, CagriSema, disappointed investors as the race for the next miracle weight-loss drug heats up.

CagriSema helped patients lose 15.7% of their weight over 68 weeks, compared to 3.1% with a placebo, Novo Nordisk reported. In an earlier trial, patients lost 22.7% of their body weight in the same time span.

Patients on Novo Nordisk’s blockbuster weight-loss drugs Ozempic and Wegovy lose about 15% of their body weight in 68 weeks. If the latest trial on CagriSema holds up, it would be just as effective as the drugs Novo Nordisk already sells.

The Danish pharmaceutical giant is looking to develop a successor drug, especially considering that Eli Lilly’s weight-loss drugs (which entered the market later) appear to be more more effective than Novo Nordisk’s. Amgen is also looking to enter the weight-loss drug arena with its new drug MariTide, which has shown promising results in its trials thus far.

News Details

News Details

Patients on Novo Nordisk’s blockbuster weight-loss drugs Ozempic and Wegovy lose about 15% of their body weight in 68 weeks. If the latest trial on CagriSema holds up, it would be just as effective as the drugs Novo Nordisk already sells.

The Danish pharmaceutical giant is looking to develop a successor drug, especially considering that Eli Lilly’s weight-loss drugs (which entered the market later) appear to be more more effective than Novo Nordisk’s. Amgen is also looking to enter the weight-loss drug arena with its new drug MariTide, which has shown promising results in its trials thus far.

More Markets

See all Markets

Max Knoblauch48m

US airlines climb as President Trump shifts his tone about the urgency of ending the shutdown

Shares of US airlines are climbing as the government shutdown stretches into a record 36th day.

Stocks of several carriers, including Delta Air Lines, United Airlines, and American Airlines, rose significantly following an apparent change of tune from President Trump, who on Wednesday told Senate Republicans that they “must get the government back open soon, and really immediately.”

It’s a shift from the president, who’s traveled frequently during the shutdown and stuck firmly to the idea that the administration wouldn’t negotiate with Democrats before the government reopened.

Airlines had tumbled on Tuesday, following comments from Transportation Secretary Duffy that the US could close parts of its airspace amid an air traffic controller shortage that’s been escalated by the shutdown.

markets

Matt Phillips1h

Top Trump trade hit by Trump tariffs

In the early days of Trump 2.0, Axon, the maker of Taser, body cameras, and other gear for police and security forces, was a top Trump trade.

That is, it was one of the group of companies whose share prices soared on expectations of big changes — in this case a surge of spending on police and immigration enforcement — under the new administration.

And sales of the company’s security products, under its Connected Products division, did rise. But in the just-reported third quarter, costs rose more. And one of those rising costs was the Trump administration’s tariffs.

In its post-earnings conference call, Axon officials blamed tariffs for a large part of the earnings miss that sent the stock plummeting by roughly 20% in the after-hours session Tuesday.

“The impact from tariffs is obviously hitting the Connected Devices business overall. This was the first quarter that we had a full quarter of impact from tariffs,” Axon CFO and COO Brittany Bagley told analysts on the call. “So as we look at the year-over-year step down, that really is attributable to tariffs.”

She continued, “As long as tariffs stay in place, I view that as sort of a onetime adjustment. So now that’s baked into the gross margins.”

Clearly the market didn’t like the sound of that. But perhaps those tariffs may not stay in place.

Late in the morning, Axon sharply cuts its losses on the day — it had been down as much as 20% — as oral arguments in the Supreme Court case to determine the legality of President Trump’s tariff regime got underway. On balance, its seems the administration’s arguments were getting a chilly reception from the justices.

Axon shares extend fall as tariffs hurt the Taser maker's quarterly profit

Axon shares extend fall as tariffs hurt the Taser maker's quarterly profit

And sales of the company’s security products, under its Connected Products division, did rise. But in the just-reported third quarter, costs rose more. And one of those rising costs was the Trump administration’s tariffs.

In its post-earnings conference call, Axon officials blamed tariffs for a large part of the earnings miss that sent the stock plummeting by roughly 20% in the after-hours session Tuesday.

“The impact from tariffs is obviously hitting the Connected Devices business overall. This was the first quarter that we had a full quarter of impact from tariffs,” Axon CFO and COO Brittany Bagley told analysts on the call. “So as we look at the year-over-year step down, that really is attributable to tariffs.”

She continued, “As long as tariffs stay in place, I view that as sort of a onetime adjustment. So now that’s baked into the gross margins.”

Clearly the market didn’t like the sound of that. But perhaps those tariffs may not stay in place.

Late in the morning, Axon sharply cuts its losses on the day — it had been down as much as 20% — as oral arguments in the Supreme Court case to determine the legality of President Trump’s tariff regime got underway. On balance, its seems the administration’s arguments were getting a chilly reception from the justices.

Rivian shares poised for best day since January as the EV maker hypes its next SUV during earnings call

Rivian shares surged more than 15% the morning following its Q3 earnings results.

Rivian Reveals All-Electric R2 Midsize SUV

Nebius Group gains after launching Token Factory platform to offer access to inference compute using open-source models

An attempt to add more breadth to the AI boom.

Breathtaking Sea Of Clouds Seen In Xingtai

The stock market wants to move on from tariffs. The Supreme Court may not let that happen.

Tariffs were a solved problem for the stock market that Supreme Court oral arguments may move back to the front burner.

President Trump Holds "Make America Wealthy Again Event" In White House Rose Garden

Latest Stories

Sherwood Media, LLC produces fresh and unique perspectives on topical financial news and is a fully owned subsidiary of Robinhood Markets, Inc., and any views expressed here do not necessarily reflect the views of any other Robinhood affiliate, including Robinhood Markets, Inc., Robinhood Financial LLC, Robinhood Securities, LLC, Robinhood Crypto, LLC, or Robinhood Money, LLC.

©2025 Sherwood Media, LLC